Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||EN6199 / 1||RA / IM|
Administered by: Other Purchased by: ??
Symptoms: Carcinoembryonic antigen increased, Catheterisation cardiac, Death, Dyspnoea exertional, Microangiopathic haemolytic anaemia, Pulmonary hypertension, Vasodilatation, Echocardiogram abnormal, ADAMTS13 activity normal
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Other Medications: MVT
Current Illness: anxiety, h/o limited stage colon CA s/p resection 2016
Preexisting Conditions: none
Diagnostic Lab Data: multiple Right heart cath and echo trial of PLEX ADAMTS level wnl multiple echo CEA very elevated 221
CDC 'Split Type':
Write-up: 3 days post vaccine, patient developed progressive DOE. Ultimately dx with microagiopathic hemolytic anemia and severe pulmonary HTN thought to be pre- and post capillary. TTP ruled out with normal ADAMTS 13, attempted IV vasodilation but ultimately died.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166